zileuton has been researched along with sulfasalazine in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (20.00) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Brůnová, B; Jandera, A; Junek, R; Kuchar, M; Kverka, M; Panajotová, V | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Abu-Serie, MM; AlFadly, ED; Bakkar, NZ; Bartolini, M; Belal, ASF; El-Yazbi, AF; Elkazaz, S; Elzahhar, PA; Ghareeb, DA; Iriepa, I; Janockova, J; Kobeissy, F; Moraleda, I; Rafeh, RW; Saudi, MNS; Shaltout, H; Soukup, O; Tramarin, A | 1 |
| Codd, R; Gotsbacher, MP; Roth, L | 1 |
| Camerini, R; Caputi, AP; Graziani, P; Squadrito, F; Zingarelli, B | 1 |
| Awni, WM; Braeckman, RA; Dubé, LM; Granneman, GR; Locke, CS | 1 |
| Colombel, JF; Desreumaux, P; Ectors, N; Geboes, K; Jouret, A; Rutgeerts, P | 1 |
| Harada, K; Inoue, T; Nagakura, N; Oketani, K | 1 |
2 review(s) available for zileuton and sulfasalazine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Histopathologic diagnosis of the activity of chronic inflammatory bowel disease. Evaluation of the effect of drug treatment. Use of histological scores].
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Biopsy; Colitis, Ulcerative; Colon; Crohn Disease; Cyclosporine; Humans; Hydroxyurea; Ileum; Immunosuppressive Agents; Inflammatory Bowel Diseases; Mesalamine; Microscopy; Sulfasalazine; Time Factors | 1999 |
1 trial(s) available for zileuton and sulfasalazine
| Article | Year |
|---|---|
The influence of multiple oral doses of zileuton on the steady-state pharmacokinetics of sulfasalazine and its metabolites, sulfapyridine and N-acetylsulfapyridine.
Topics: Administration, Oral; Adult; Anti-Infective Agents; Anti-Inflammatory Agents; Chromatography, High Pressure Liquid; Double-Blind Method; Drug Interactions; Half-Life; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Male; Middle Aged; Sulfapyridine; Sulfasalazine | 1995 |
12 other study(ies) available for zileuton and sulfasalazine
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Antileukotrienic N-arylethyl-2-arylacetamides in the treatment of ulcerative colitis.
Topics: Acetamides; Animals; Colitis, Ulcerative; Disease Models, Animal; Edema; Hydrophobic and Hydrophilic Interactions; Leukotriene B4; Neutrophils; Rats; Receptors, Leukotriene B4; Structure-Activity Relationship | 2007 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Tackling neuroinflammation and cholinergic deficit in Alzheimer's disease: Multi-target inhibitors of cholinesterases, cyclooxygenase-2 and 15-lipoxygenase.
Topics: Acetylcholine; Alzheimer Disease; Animals; Cell Line; Cholinesterase Inhibitors; Cyclooxygenase 2 Inhibitors; Drug Design; Humans; Inflammation; Lipoxygenase Inhibitors; Mice; Molecular Docking Simulation; Neurons; PC12 Cells; Rats; Semicarbazides; Triazoles | 2019 |
Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
Topics: Chromatography, Affinity; Coordination Complexes; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Discovery; Humans; Imino Acids; Metalloproteins; Metals, Heavy; Models, Molecular; Molecular Structure; Structure-Activity Relationship | 2020 |
Effects of zileuton, a new 5-lipoxygenase inhibitor, in experimentally induced colitis in rats.
Topics: Animals; Colitis; Colon; Eicosanoids; Hydroxyurea; Inflammatory Bowel Diseases; Leukocytes; Lipoxygenase Inhibitors; Male; Peroxidase; Rats; Rats, Wistar; Sulfasalazine; Trinitrobenzenesulfonic Acid | 1993 |
In vitro effects of E3040, a dual inhibitor of 5-lipoxygenase and thromboxane A(2) synthetase, on eicosanoid production.
Topics: Animals; Arachidonate 5-Lipoxygenase; Benzothiazoles; Dinoprostone; Dose-Response Relationship, Drug; Eicosanoids; Humans; Hydroxyurea; Indomethacin; Leukocytes; Leukotriene B4; Lipoxygenase Inhibitors; Male; Mesalamine; Methacrylates; Neutrophils; Peritoneal Cavity; Prostaglandin-Endoperoxide Synthases; Pyridines; Rats; Rats, Inbred F344; Sheep; Sulfasalazine; Thiazoles; Thromboxane B2; Thromboxane-A Synthase | 2001 |